HAVCR2 and breast carcinoma: For TIDCs, previous studies showed that the TIM-3 expression inhibits the activation and maturation of DCs, interfering with the ability of endocytosis of extracellular DNA, thus suppressing the anti-tumor immunity in breast cancer [33, 34].